The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
Eli Lilly announced that its next-generation obesity drug retatrutide met both primary and secondary goals in its first late-stage trial for type 2 diabetes patients. The drug achieved significant A1c reductions of 1.7% to 2% and impressive weight loss of up to 16.8% at 40 weeks. This marks a promising advancement for patients struggling with both blood sugar control and weight management.
GLP-1 drugs like Ozempic and Wegovy are reshaping eating habits, slashing demand for pastries while surging sales of protein-rich yogurt and cottage cheese. Studies show users cut grocery spending by 6-9%, favoring nutrient-dense dairy. Dairy giants like Arla and Ehrmann are capitalizing with GLP-1-friendly products.
Semaglutide, the active ingredient in Ozempic and Wegovy, is associated with a 44% decreased risk of worsening depression and 38% lower anxiety risk, per a large Swedish study. Researchers suggest potential neurobiological effects beyond weight loss. Discover how these GLP-1 agonists may support mental health in diabetes and obesity patients.
A legal 'loophole' is fueling a boom in unregulated injectable peptides sold online as 'research only' products, despite warnings they're unsafe for human use. Fitness enthusiasts inject BPC-157 and TB-500 for healing, while unapproved Retatrutide draws weight loss seekers. Experts urge caution amid contamination risks and MHRA crackdowns.
India's Semaglutide patent expires March 20, opening doors for low-cost generics from pharma giants like Zydus, Torrent, Sun Pharma, and Dr. Reddy's. With over 23% of women and 22% of men overweight per NFHS-5, and 45 crore adults projected obese by 2050, affordable options could reshape the fight against obesity and diabetes. Discover the price revolution and challenges ahead.
A St. Johns County man, Adam K. Taylor, is now facing federal misdemeanor charges for misbranding and selling off-brand versions of Ozempic (semaglutide) and other GLP-1 drugs without prescriptions. Operating AKT Labs as 'research purposes only,' he instructed undercover officers on weight loss use. This case highlights dangers of unregulated peptides sourced from China.
Consumers are shifting from short-term fixes to proactive long-term gut health strategies, accelerated by GLP-1 medications, according to Kerry representatives Mathieu Millette, Ph.D., and Haelim Choi. Kerry research highlights top-valued benefits, while GLP-1 demand drives GI support innovations, including biotics tested in human trials to counter side effects.
Hims & Hers Health (NYSE: HIMS) is now offering a waitlist for affordable branded Wegovy and Ozempic at $149, thanks to a new Novo Nordisk deal. This expands access to these popular GLP-1 weight-loss drugs amid high demand. Meanwhile, HIMS stock shows short-term rebound potential in a downtrend—dive into the technicals and analyst views.
Researchers at Mass General Brigham have launched a revolutionary genetic risk calculator that not only forecasts obesity and Type 2 diabetes but also their long-term health consequences. Powered by data from over 8.5 million participants worldwide, this polygenic risk score outperforms existing tools, especially in diverse populations. Discover why this could enable earlier interventions like GLP-1 medications.
